- Published at
- by investing.com
mixed
mixed
News for Sorrento Therapeutics, Inc. (SRNE)
- Published at
- by globenewswire.com
positivepositiveScilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative
Scilex management is determined to enhance its stockholders’ value and protect their stockholder rights, and is taking steps to combat manipulative and...- Published at
- by globenewswire.com
mixedmixedProstate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the Domain
Prostate cancer is one of the most common cancers among men worldwide, especially in aging populations. The increasing global elderly population leads to...- Published at
- by insurancejournal.com
positivepositiveJ&J’s Court-Shopping Strategy Pits New Jersey Home Against Texas
Johnson & Johnson's bold move to skirt a US court in New Jersey and seek a potentially friendlier venue in Texas to settle claims its baby powder gave- Published at
- by globenewswire.com
mixedmixedBy 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion, at 1.80% CAGR: Prophecy Market Insights
“CAR-T Cell Therapy Market” from 2024-2034 with covered segments By Drug Type (Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and...- Published at
- by globenewswire.com
positivepositiveCAR-T Cell Therapy Market to Achieve USD 85.8 Billion by 2033, Driven by 32.0% CAGR | Dimension Market Research
Advancements and Projections in the CAR-T Cell Therapy Market: Insights, Trends, Opportunities, and Recent Developments...- Published at
- by investing.com
mixedmixedVirpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments By Investing.com
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments- Published at
- by globenewswire.com
mixedmixedGlobal CAR T-Cell Therapy Market Size To Worth USD 21.92 Billion By 2033 | CAGR of 17.72%
The Global CAR T-Cell Therapy Market Size was Valued at USD 4.29 Billion in 2023 and the Worldwide CAR T-Cell Therapy Market Size is Expected to Reach USD...- Published at
- by investing.com
mixedmixedScilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend By Investi
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend- Published at
- by marketscreener.com
mixedmixedVirpax Pharmaceuticals Reports 2023 Year-End Results
Virpax® Pharmaceuticals, Inc. , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral barrier...- Published at
- by investing.com
positivepositiveScilex reaches settlement in Sorrento bankruptcy case By Investing.com
Scilex reaches settlement in Sorrento bankruptcy case- Published at
- by globenewswire.com
mixedmixedScilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previ
PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue generating...- Published at
- by benzinga.com
negativenegativeScilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Sha
PALO ALTO, Calif., March 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX,- Published at
- by globenewswire.com
mixedmixedOncolytic Virus Immunotherapy Market Expected to Reach USD 572.2 million by 2031, Expanding at a 21.1% CAGR | Transparency Market Research, Inc.
The two main drivers driving up the value of the oncolytic virus immunotherapy market are the rising incidence of cancer and the increase in healthcare...- Published at
- by globenewswire.com
negativenegativeNatural Killer (NK) Cell Therapeutics Market: Pioneering Immunotherapy for Cancer Treatment with market Size & Share to Exceed USD 114119.6 Million by 2034, at CAGR of 41.70% – By PMI
“Natural Killer (NK) Cell Therapeutics Market” from 2024-2034 with covered segments (Natural Killer (NK) Cell Therapeutics Market, By Type (NK Cell...- Published at
- by globenewswire.com
mixedmixedMarginal Zone Lymphoma Market Size Expected to Demonstrate Optimal Growth in the 7MM During the Study Period (2019–2032), Analysis by DelveInsight
The marginal zone lymphoma pipeline possesses potential drugs in mid-stage developments to be launched in the near future. The total marginal zone lymphoma...- Published at
- by globenewswire.com
mixedmixedDiffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out - AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Tak
The DLBCL market has a diverse pipeline, with the emergence of novel classes such as bi-specific antibodies, cancer vaccines, and allogeneic CAR-Ts in the...- Published at
- by globenewswire.com
mixedmixedGlobal CAR T-Cell Therapy Market Size on a Meteoric Rise: Envisioning $2406.39 Million by 2030 with a Striking CAGR of 26.20%
[222 + Pages Report] According to a market research study published by Zion Market Research, the demand analysis of Global CAR T-Cell Therapy Market size &...- Published at
- by prnewswire.com
mixedmixedCAR T-Cell Therapy Market size to grow at a CAGR of 13.44% from 2022 to 2027; Growing Awareness Regarding CAR T-cell Therapy to boost the market growth- Technavio.
/PRNewswire/ -- The CAR T-cell therapy market is expected to grow by USD 1,999 million from 2022 to 2027, progressing at a CAGR of 13.44% as per the latest...- Published at
- by globenewswire.com
mixedmixedDelveInsight Evaluates a Robust Antibody-drug Conjugates in Oncology Clinical Trial Pipeline as 30+ Influential Pharma Players to Set Foot in the 7MM
The introduction of ADCs into the market and the promising clinical results of more ADC prospects have increased industry interest in ADCs as a treatment...